# US 2018/0022790 A1 · Equine immunoglobulin compositions and uses for treating filovirus-mediated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022790 A1
- Document ID: US20180022790A1
- Status: Published application
- Kind: A1
- Application number: 15/547,379
- Filed: 2016-01-28
- Published: 2018-01-25
- Earliest claimed: 2015-01-28
- Assignees: Integrated Biotherapeutics, Inc.; Auburn University
- Applicants: Integrated Biotherapeutics, Inc.; Auburn University
- Inventors: Frederick Wayne HOLTSBERG; Mohammad Javad AMAN; Paul H. WALZ; Stephanie R. OSTROWSKI
- Web page: https://patentgrep.com/patent/US20180022790A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/39516: {from serum, plasma}
- A61K 39/42: viral
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/12: Antidiarrhoeals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 11/04: for throat disorders
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/14: for RNA viruses
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/10: RNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2760/14022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/14034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/14134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/14222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/14234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides a composition comprising immunoglobulin from an equine that has been hyper-immunized with a filovirus immunogen. The disclosure further provides methods of making such compositions and methods of using such compositions, e.g., for treating Ebola virus infection.

## Claims

### Claim 1

A pharmaceutical composition comprising polyclonal immunoglobulin from an equine that has been hyper-immunized with a filovirus glycoprotein.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the immunoglobulin is purified from serum or plasma of the equine that has been hyper-immunized with the filovirus glycoprotein.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the purified immunoglobulin is IgG, or a fragment thereof.

### Claim 4 (depends on 3)

The composition of claim 3, wherein at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20%, or more of the purified IgG binds to the filovirus glycoprotein.

### Claim 5 (depends on 2, 3, 4)

The composition of any one of claims 2 to 4, wherein the purified immunoglobulin can prevent or minimize symptoms in a subject infected with a filovirus.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein the filovirus is Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), Tai Forrest virus (TAFV), Reston virus (RESTV), or Marburg virus (MARV).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6, wherein the equine is immunized with a mucin-like domain-deleted filovirus spike glycoprotein.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1 to 7, wherein the transmembrane domain of the spike glycoprotein is deleted.

### Claim 9 (depends on 7, 8)

The composition of claim 7 or claim 8, wherein the spike glycoprotein comprises the GP1 subunit or a fragment thereof from MARV, EBOV, SUDV, BDBV, TAFV, RESTV, or a combination of GP1 subunits thereof.

### Claim 10 (depends on 7, 8)

The composition of claim 7 or claim 8, wherein the spike glycoprotein comprises the GP1 subunit or a fragment thereof and the GP2 subunit or a fragment thereof from MARV, EBOV, SUDV, BDBV, TAFV, RESTV, or a combination of GP1 and GP2 subunits thereof.

### Claim 11 (depends on 7, 8, 9, 10)

The composition of any one of claims 7 to 10, wherein the spike glycoprotein comprises an amino acid sequence that is at least 90%, at least 95%, or 100% identical to SEQ ID NOS: 2, 4, 6, 8, 10, or 12.

### Claim 12 (depends on 7, 8, 9, 10, 11)

The composition of any one of claims 7 to 11, wherein the equine is immunized with the spike glycoprotein on days 0, 21, 42, and 63.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the polyclonal immunoglobulin is recovered as plasma on day 90 via plasmapheresis.

### Claim 14 (depends on 12, 13)

The composition of claim 12 or claim 13, wherein the immunogen comprises MARV GP-ATM, and wherein the recovered plasma has an EC50 titer for binding to MARV GP-ATM of at least 102, at least 5×102, at least 103, at least 5×103, least 104, at least 5×104, least 105, or at least 5×105, as determined by ELISA.

### Claim 15 (depends on 13, 14)

The composition of claim 13 or claim 14, wherein the immunogen comprises MARV GP-ATM, and wherein the purified IgG binds to MARV GP-ΔTM with an EC50 of less than 3 μg/ml, less than 2.5 μg/ml, less than 2 μg/ml, less than 1.5 μg/ml, or less than 1 μg/ml, or less than 0.5 μg/ml, as measured ELISA.

### Claim 16 (depends on 12, 13, 14, 15)

The composition of any one of claims 12 to 15, wherein two doses of about 100 mg/kg administered to a mouse following a lethal challenge with a filovirus can protect the mouse against the lethal challenge.

### Claim 17 (depends on 7, 8, 9, 10, 11)

The composition of any one of claims 7 to 11, wherein the equine is immunized in a prime-boost regimen.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the prime-boost regimen comprises priming with a filovirus virus-like particle (VLP) and boosting with the spike glycoprotein.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the VLP comprises a filovirus glycoprotein and a filovirus VP40.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the VLP further comprises the filovirus nucleoprotein (NP).

### Claim 21 (depends on 18)

The composition of claim 18, wherein the prime dose is administered on day zero and day 21, and the boost dose is administered on day 42 and day 63.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the polyclonal immunoglobulin is recovered as plasma on day 90 via plasmapheresis.

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

The composition of any one of claims 17 to 22, wherein the priming immunogen comprises an EBOV VLP comprising GP, VP40, and NP, the boosting immunogen comprises EBOV GP-ΔMuc, and wherein the recovered plasma has an EC50 titer for binding to EBOV GP-ΔTM of at least 103, at least 5×103, least 104, at least 5×104, least 105, or at least 5×105, as determined by ELISA.

### Claim 24 (depends on 17, 18, 19, 20, 21, 22, 23)

The composition of any one of claims 17 to 23, wherein the priming immunogen comprises an EBOV VLP comprising GP, VP40, and NP, the boosting immunogen comprises EBOV GP-ΔMuc, and wherein the purified IgG binds to EBOV GP-ΔTM or EBOV GP-ΔMuc with an EC50 of less than 1 μg/ml, less than 0.9 μg/ml, less than 0.8 μg/ml, less than 0.7 μg/ml, less than 0.6 μg/ml, less than 0.5 μg/ml, less than 0.4 μg/ml, less than 0.3 μg/ml, less than 0.2 μg/ml, less than 0.1 μg/ml, or less than 0.09 μg/ml, as measured ELISA.

### Claim 25 (depends on 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 17 to 24, wherein two doses of about 100 mg/kg administered to a mouse following a lethal challenge with a filovirus can protect the mouse against the lethal challenge.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for preparing the composition of any one of claims 1 to 25, comprising
(a) administering an amount of a filovirus immunogen to an equine sufficient to hyperimmunize the equine against protective antigens of the filovirus, wherein the immunogen comprises a filovirus spike glycoprotein; and
(b) recovering immunoglobulin from the equine.

### Claim 27 (depends on 26)

The method of claim 26, wherein the immunoglobulin is recovered as plasma.

### Claim 28 (depends on 26, 27)

The method of claim 26 or claim 27, further comprising purifying the immunoglobulin recovered from the equine.

### Claim 29 (depends on 28)

The method of claim 28, wherein the purified immunoglobulin comprises IgG or a fragment thereof.

### Claim 30

A method for preventing, treating, or managing a filovirus-mediated disease in a subject, comprising administering to a subject in need of treatment a polyclonal immunoglobulin from an equine that has been hyper-immunized with a filovirus glycoprotein.

### Claim 31 (depends on 30)

The method of claim 30, wherein the immunoglobulin is purified from serum or plasma of the equine that has been hyper-immunized with the filovirus glycoprotein.

### Claim 32 (depends on 31)

The method of claim 31, wherein the purified immunoglobulin is IgG, or a fragment thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20%, or more of the purified IgG binds to the filovirus glycoprotein.

### Claim 34 (depends on 31, 32, 33)

The method of any one of claims 31 to 33, wherein the purified immunoglobulin can prevent or minimize symptoms in a subject infected with a filovirus.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The method of any one of claims 30 to 34, wherein the filovirus is MARV, EBOV, SUDV, BDBV, TAFV, or RESTV.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The method of any one of claims 30 to 35, wherein the equine is immunized with a mucin-like domain-deleted filovirus spike glycoprotein.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 30 to 36, wherein the transmembrane domain of the spike glycoprotein is deleted.

### Claim 38 (depends on 36, 37)

The method of claim 36 or claim 37, wherein the spike glycoprotein comprises the GP1 subunit or a fragment thereof from MARV, EBOV, SUDV, BDBV, TAFV, RESTV, or a combination of GP1 subunits thereof.

### Claim 39 (depends on 36, 37)

The method of claim 36 or claim 37, wherein the spike glycoprotein comprises the GP1 subunit or a fragment thereof and the GP2 subunit or a fragment thereof from MARV, EBOV, SUDV, BDBV, TAFV, RESTV, or a combination of GP1 and GP2 subunits thereof.

### Claim 40 (depends on 36, 37, 38, 39)

The method of any one of claims 36 to 39, wherein the spike glycoprotein comprises an amino acid sequence that is at least 90%, at least 95%, or 100% identical to SEQ ID NOS: 2, 4, 6, 8, 10, or 12.

### Claim 41 (depends on 36, 37, 38, 39, 40)

The method of any one of claims 36 to 40, wherein the equine is immunized with the spike glycoprotein on days 0, 21, 42, and 63.

### Claim 42 (depends on 40, 41)

The method of claim 40 or claim 41, wherein the polyclonal immunoglobulin is recovered as plasma on day 90 via plasmapheresis.

### Claim 43 (depends on 42)

The method of claim 42, wherein the immunogen comprises MARV GP-ΔTM, and wherein the recovered plasma has an EC50 titer for binding to MARV GP-ΔTM of at least 102, at least 5×102, at least 103, at least 5×103, least 104, at least 5×104, least 105, or at least 5×105, as determined by ELISA.

### Claim 44 (depends on 42, 43)

The method of claim 42 or claim 43, wherein the immunogen comprises MARV GP-ATM, and wherein the purified IgG binds to MARV GP-ΔTM with an EC50 of less than 3 μg/ml, less than 2.5 μg/ml, less than 2 μg/ml, less than 1.5 μg/ml, or less than 1 μg/ml, or less than 0.5 μg/ml, as measured ELISA.

### Claim 45 (depends on 42, 43, 44)

The method of any one of claims 42 to 44, wherein two doses of about 100 mg/kg administered to a mouse following a lethal challenge with a filovirus can protect the mouse against the lethal challenge.

### Claim 46 (depends on 36, 37, 38, 39, 40)

The method of any one of claims 36 to 40, wherein the equine is immunized in a prime-boost regimen.

### Claim 47 (depends on 46)

The method of claim 46, wherein the prime-boost regimen comprises priming with a filovirus VLP and boosting with the spike glycoprotein.

### Claim 48 (depends on 47)

The method of claim 47, wherein the VLP comprises a filovirus glycoprotein and a filovirus VP40.

### Claim 49 (depends on 48)

The method of claim 48, wherein the VLP further comprises the filovirus nucleoprotein (NP).

### Claim 50 (depends on 46, 47, 48, 49)

The method of any one of claims 46 to 49, wherein the prime dose is administered on day zero and day 21, and the boost dose is administered on day 42 and day 63.

### Claim 51 (depends on 46, 47, 48, 49, 50)

The method of any one of claims 46 to 50 wherein the polyclonal immunoglobulin is recovered as plasma on day 90 via plasmapheresis.

### Claim 52 (depends on 50, 51)

The method of claim 50 or claim 51, wherein the priming immunogen comprises an EBOV VLP comprising GP, VP40, and NP, the boosting immunogen comprises EBOV GP-ΔMuc, and wherein the recovered plasma has an EC50 titer for binding to EBOV GP-ATM of at least 103, at least 5×103, least 104, at least 5×104, least 105, or at least 5×105, as determined by ELISA.

### Claim 53 (depends on 50, 51)

The method of claim 50 or claim 51, wherein the priming immunogen comprises an EBOV VLP comprising GP, VP40, and NP, the boosting immunogen comprises EBOV GP-ΔMuc, and wherein the purified IgG binds to EBOV GP-ΔTM or EBOV GP-ΔMuc with an EC50 of less than 1 μg/ml, less than 0.9 μg/ml, less than 0.8 μg/ml, less than 0.7 μg/ml, less than 0.6 μg/ml, less than 0.5 μg/ml, less than 0.4 μg/ml, less than 0.3 μg/ml, less than 0.2 μg/ml, less than 0.1 μg/ml, or less than 0.09 μg/ml, as measured ELISA.

### Claim 54 (depends on 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 46 to 53, wherein two doses of about 100 mg/kg administered to a mouse following a lethal challenge with a filovirus can protect the mouse against the lethal challenge.

### Claim 55 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 30 to 54, wherein the filovirus-mediated disease comprises one or more symptoms selected from the group consisting of: fever, internal hemorrhaging, edema, organ failure, headache, malaise, myalgia, nausea, vomiting, bleeding of needle puncture sites, hematemesis, melena, petechiae, ecchymosis, maculopapular rash, disseminated intravascular coagulation, shock, jaundice, conjunctivitis, diarrhea, pharyngitis, convulsions, delirium, coma, oligura, and epistaxis.

### Claim 56 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 30 to 55, wherein the subject is a human.
